BioMmune Technologies Inc. is a biopharmaceutical company engaged in the exciting new field of immunotherapy, the discovery and development of new therapeutics that enable the body’s own immune system to recognize and attack infections, cancers and autoimmune diseases.
BioMmune is advancing three technologies developed at The University of British Columbia:
- The utilization of proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells.
- The regulation of calcium channel activity which is very important for controlling cells involved in the immune system. By regulating these calcium channels, immune activity can be controlled in ways to improve their ability to combat cancers, infections and autoimmune diseases.
- The modulation of CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding molecules that regulate CD74 activity will aid the immune system to combat infections and cancers and to control autoimmune diseases.
BioMmune is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “IMU”.